Qualia NAD+® Increases NAD+ In Human Participants: A Randomized, Double-Blind, Placebo-Controlled Study

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Nicotinamide adenine dinucleotide (NAD) is a crucial coenzyme involved in cellular energy homeostasis whose levels decline notably with aging, which has prompted interest in NAD+ boosting to combat age-related diseases and dysfunction. Numerous clinical trials have demonstrated safety and efficacy for B3 vitamins like nicotinamide riboside (NR) to increase NAD+ levels and augment the NAD+ metabolome. Limited impact on clinically relevant outcomes or quality of life have been demonstrated, however. This randomized, double-blind, placebo-controlled study examined the effects of Qualia NAD+® on whole blood NAD+ levels and quality of life measures. Twenty-five healthy adults aged 40 - 65 (56% female) consumed Qualia NAD+ (n = 9) or placebo (n = 16) for 28 consecutive days. NAD+ levels were measured using a novel self-administered, non-invasive blood spot assay test conducted at baseline and at study end, while quality of life measures were reported bi-weekly. Overall, Qualia NAD+ significantly increased NAD+ levels an average of 74% compared to a 4% increase observed in the placebo group (p < 0.001). Within-groups comparisons for Qualia NAD+, and changes in NAD+ levels comparing Qualia NAD+ and placebo were also significant (p < 0.001). Improvements in the overall and somatic categories (p = 0.02 and p = 0.04) were observed for males only comparing baseline to day 28, while no other quality of life changes were noted. Qualia NAD+, a novel nutraceutical formulated with multiple vitamins, nutrients, and botanical compounds, effectively increased whole blood NAD+ levels and improved some symptoms of aging in males. Clinicaltrials.gov identifier: NCT06812416 .

Article activity feed